title: Two different intensity-modulated radiotherapy strategies for patients with high-risk prostate cancer.
abstract: OBJECTIVE
  To compare toxicity profiles of two different intensity-modulated radiation therapy (IMRT) strategies in patients with high-risk prostate cancer.
  
  
  METHODS
  From May 2010 to September 2012, 43 patients with high-risk prostate cancer were treated with IMRT and concurrent hormone therapy; 23 patients were treated by conventional fractionation (IMRT/C) and 20 patients by simultaneous integrated boost (IMRT/SIB). Acute and late toxicities were compared for each group.
  
  
  RESULTS
  Severe acute genitourinary toxicity was recorded in 8.6% and 2% of patients in the IMRT/C and IMRT/SIB group, respectively. Genitourinary toxicity G2 was observed in 39.1% (IMRT/C group) and 25% (IMRT/SIB group) of patients. Severe acute gastrointestinal toxicity was not observed; Grade 2 acute gastrointestinal toxicity was recorded in 21.7% (IMRT/C group) and 10% (IMRT/SIB group). Grade 2 late genitourinary toxicity was observed in 26% (IMRT/C group) and 15% (IMRT/SIB group), whereas G2 late gastrointestinal toxicity in 34.5% and 30% of patients, respectively. No significant differences in incidence and severity of genitourinary and gastrointestinal toxicity were detected between the two IMRT treatment strategies.
  
  
  CONCLUSIONS
  IMRT/SIB was well-tolerated with favorable rates of acute and late toxicity, both genitourinary and gastrointestinal. Compared to IMRT/C, IMRT/SIB maintained the same efficacy and reduced the overall treatment time.
authors: Department of Radiotherapy, Policlinico Umberto I Sapienza University of Rome, Rome, Italy fradefelice@hotmail.it.
authors: Francesca
authors: F
authors: De Felice
authors: Department of Radiotherapy, Policlinico Umberto I Sapienza University of Rome, Rome, Italy.
authors: Daniela
authors: D
authors: Musio
authors: Department of Radiotherapy, Policlinico Umberto I Sapienza University of Rome, Rome, Italy.
authors: Rossella
authors: R
authors: Caiazzo
authors: Department of Radiological Sciences, Oncology and Pathology, Policlinico Umberto I Sapienza University of Rome, Rome, Italy.
authors: Valeria
authors: V
authors: Panebianco
authors: Department of Radiotherapy, Policlinico Umberto I Sapienza University of Rome, Rome, Italy.
authors: Nicola
authors: N
authors: Raffetto
authors: Department of Radiotherapy, Policlinico Umberto I Sapienza University of Rome, Rome, Italy Spencer-Lorillard Foundation, Rome, Italy.
authors: Vincenzo
authors: V
authors: Tombolini
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D059248:Chemoradiotherapy; D019583:Dose Fractionation, Radiation; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D011832:Radiation Injuries / Q000209:etiology; D050397:Radiotherapy, Intensity-Modulated / Q000009:adverse effects / Q000379:methods
chemical_list: D018931:Antineoplastic Agents, Hormonal
keywords: Intensity-modulated radiotherapy; high-risk; prostate cancer; simultaneous; toxicity